CTLA4 and gastric cancer: Additionally, using the TCIA database, we calculated CTLA4- and PD-1-based immunophenotype scores (IPS) for GC patients and compared the response to anti-CTLA4 and anti-PD-1 immunotherapy between patients with high and low ILF2 expression levels.